Vp Product Development Jobs In Switzerland - 31 Job Positions Available

About Idorsia Pharmaceuticals Ltd Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ (daridorexant), a different kind of

Sulzer is a leading engineering company with a proud heritage of innovation. Join our global team to grow your expertise and develop innovative solutions that enable a prosperous and more sustainable society. About the role Join

Were Hiring: Chief Product Officer (CPO) / Deputy IT Director Industry: FinTech / Payments Location: Switzerland Compensation: CHF 200,000–240,000 gross per year + Performance Bonus We are partnering with a rapidly growing international FinTech & Payments organisation

Job Description Purpose of the role To assess and approve/decline credit applications based on established credit policies, risk appetite, and regulatory requirement and analysing financial information, evaluating creditworthiness, and recommending credit terms and conditions to ensure

Company Description Why Join Us At Check Point, what you do matters. Every day, we protect over 100,000 organizations worldwide from increasingly sophisticated cyber and AI-driven threats, securing their AI transformation. Our prevention-first approach safeguards hybrid

Join Proton and build a better internet where privacy is the default Proton was founded in 2014 by scientists from CERN on a simple truth: privacy is a fundamental human right. Since then, weve built the

VANS is looking for an exceptional Head of Retail to join our team based in Stabio, Switzerland. Let’s Talk about the Role The Head of Retail is accountable for delivering retail revenue and profitability for the

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of

Senior Director, Finance – CIO Group, Operations & Technology About CIO, Operations & Technology Do you want to shape how a global technology organisation invests, scales, and delivers impact? Join Thomson Reuters as a strategic finance

Project Management Officer (PMO) — IT Were excited to announce an opening for a Project Management Officer (PMO) to join our IT Team at the Geneva HQ working across our Geneva team and remote sites in

Mavericks Wanted When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement.read on In 2015, we pioneered a “moneyball for biotech”

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)

Thomson Reuters is enhancing its Cyber Defense capability in response to an AI-driven threat landscape that has fundamentally changed the speed, scale, and nature of cyberattacks. The Distinguished Engineer, AI Threat Defense is an individual contributor

This position can be based remotely in territory (Switzerland, Germany, or Austria), or remotely near the Swiss border in France. About Us GitGuardian is a global cybersecurity scale-up. The company is based in Paris, New-York City,

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)